重塑生命科学公司(RSLS)公布了其2024年第一季度的财务业绩，强调了大幅削减成本和提高盈利能力的战略重点。首席执行官Paul Hickey强调了Lap-Band 2.0 FLEX的成功限量发布，以及公司为全面投放美国市场所做的努力。尽管由于GLP-1药物的竞争，第一季度的收入减少了15%，但重塑已经设法将其毛利率提高到60%，并将运营费用减少了一半以上。公司还在寻求加拿大和欧盟的市场扩张，并在Maxim集团的协助下探索战略并购。
由于GLP-1药物的影响，重塑生命科学公司报告第一季度收入同比下降15%。
毛利率提高到60%，销售、营销和一般费用大幅减少。
预计营业费用将下降到2024年，P将下降55.4%。
Lap-Band 2.0 FLEX的发布进展顺利，预计将于2024年在美国全面发布，推动销售。
目前，该公司正努力获得加拿大和欧盟监管机构的批准，并在探索并购机会。
该公司的净营运资本为440万美元，并且没有债务。
预计收入增长和co在整个2024年继续减少运营费用。
Lap-Band 2.0 FLEX在美国全面推出，预计将增加销量。
寻求在加拿大和欧盟销售产品的监管批准。
协助美信集团寻找战略性并购机会。
第一季度收入由于GLP-1药物对销量的影响，收缩了15%。
尽管预计会减少，但运营费用仍然是一个挑战。
由于成本降低，毛利率增加到60%。
销售和营销费用下降53%。
一般和行政费用减少了56%。
2024年第一季度的收入低于上年同期。
GLP-1药物对销量的影响继续挑战收入增长。
该公司专注于通过削减成本和推出Lap-Band 2.0 FLEX来推动增长和盈利。
重塑自我对其Lap-Band产品的市场潜力充满信心，并积极投资于商业战略。
公司感谢股东的支持持续支持并致力于为股东创造价值。
重塑生命科学公司概述了一项明确的战略，以应对减肥市场的竞争格局。该公司专注于成本效益和市场扩张，将自己定位于利用日益增长的肥胖治疗需求。随着重塑公司继续精简运营并投资于增长计划，利益相关者将密切关注这些努力对公司底线的影响。
从2024年第一季度财报中可以看出，重塑生命科学公司(RSLS)一直致力于财务纪律和战略增长。通过InvestingPro深入了解该公司的财务状况和市场表现，可以发现投资者可能感兴趣的几个关键指标和见解:
InvestingPro数据显示，截至2024年第一季度，过去12个月的毛利率为65.85%，明显高于第一季度报告的60%。这表明，尽管面临收入挑战，但在较长一段时间内，重塑生命科学一直保持着强劲的利润率。
该公司的市值约为413万美元，截至2024年第一季度的过去12个月的市净率为0.91，这可能表明该股票相对于公司的账面价值可能被低估。
InvestingPro Tips强调，RSLS在资产负债表上持有的现金多于债务，这可能是金融稳定的一个积极迹象。然而，同样值得注意的是，分析师预计该公司今年不会盈利，而且该公司一直在迅速烧钱。
对于寻求更多信息的投资者，还有额外的InvestingPro Tips，可以为重塑生命科学的财务业绩和市场地位提供进一步的见解。感兴趣的读者可以在InvestingPro平台上找到这些建议。
要获得这些有价值的见解和更多信息，使用优惠券代码PRONEWS24可以获得每年或两年一次的Pro和Pro+订阅额外10%的折扣。此外，RSLS还列出了11个额外的InvestingPro Tips，投资者可以在指尖上获得丰富的信息，以指导他们的投资决策。
接线员:下午好，感谢您参加2024年第一季度重塑生命科学电话会议。我想把电话交给Rx通讯公司的迈克尔·米勒。
迈克尔·米勒:下午好，感谢大家参加2024年第一季度重塑生命科学公司的收益电话会议。今天，我很高兴总裁兼首席执行官保罗·希基(Paul Hickey)和首席财务官汤姆·斯坦科维奇(Tom Stankovich)出席会议。Paul将提供公司活动的概述和最新情况，Tom将回顾这段时间的财务结果，然后我们将电话转回给Paul做一些总结发言，之后我们将开始电话问答环节。提醒一下，本次电话会议以及重塑生命科学SEC文件和网站，包括网站的投资者信息部分包含1995年《私人证券诉讼改革法案》意义上的前瞻性陈述。由于已知和未知的风险、不确定性和其他因素，实际结果可能与讨论的结果存在重大差异。这些以及其他风险和不确定性在公司提交给美国证券交易委员会的文件中有更全面的描述，包括公司最近的10-K表格年度报告中确定的风险因素。作为额外的提醒，重塑股票在纳斯达克上市，交易代码为RSLS。现在我把话筒交给Paul Hickey，重塑生命科学公司的总裁兼首席执行官。保罗?
Paul Hickey: Thank you, Mike, and thanks to all of you for joining us this afternoon for our earnings call for the first quarter of 2024. During the first quarter and subsequently, we have remained focused on delivering shareholder value and have ReShape on a path to profitability and long-term sustainability. Key to our success include our efforts to stabilize revenues as well as our disciplined approach to continually leveraging resources and focus on reducing costs as we outlined in March. To that end, we continue to fine tune our lead generation activities and invest in our growth drivers, including the commercial launch of our physician-led redesign Lap-Band 2.0 FLEX. At the same time, we continue our high priority search for strategic and synergistic M&A opportunities. As we have mentioned before, we have engaged the Maxim Group on an exclusive basis to assist in this process. As one can imagine, we've had a high level of activity and we'll continue this effort to find the right partner to join us in our mission at ReShape to improve the quality of life for individuals, funding obesity worldwide. With the stigma around obesity and medical intervention being normalized by the surge of GLP-1 receptor agonist usage, we are steadfast in our confidence that the numbers of people seeking medical professionals, especially bariatric surgeons, will continue to increase the GLP-1 short term impact on the market last year, made it necessary for us to undertake additional strategic cost reductions, including a further reduction in staff leading to a projected 55.4% decrease in operating expenses for 2024 as compared to last year. Tom and I will provide further details during this call, but this reorganization and decrease in expenses will allow us to focus on and optimize the commercialization of our Lap-Band 2.0 FLEX created to improve the patient experience, while continuing to market our current Lap-Band. I'm happy to report that the limited launch of the Lap-Band 2.0 FLEX continues to progress well, and the initial surgeon feedback has been positive. Added to this, our revamped patient friendly website is receiving meaningful traffic, while our co-op marketing program involving cost-sharing with key Lap-Band centers has proved effective and scalable. Before I recap our first quarter and subsequent highlights, I'd like to remind listeners about the important events occurring within the obesity market today. As most of you already understand, the global obesity market is growing at an alarming rates and carries with it significant medical repercussions and associated economic costs. Obesity remains a complex lifelong disease that requires personalized treatment to ensure long term weight loss goals are achieved. I'm sure you're also aware of the growing popularity of GLP-1 receptor agonists that have brought significant benefits to those suffering from Type 2 diabetes and it help those who have obesity. We believe that GLP-1 adoption is expanding the medical weight loss market by vastly reducing the stigma that often occurs around obesity and medical intervention, including bariatric surgery. However, it's becoming very clear that weight loss due to GLP-1 drug usage has limitations, especially related to cost accessibility and the fact that weight loss plateaus by 12 months to 18 months. Additionally, the real-world long-term tolerability is low and one large analysis, only 27% of patients prescribed GLP-1 receptor agonists were adherent after one year. We continue to believe based on this and other evidence that the market opportunity for the Lap-Band will increase over time, especially with the newly launched next-generation Lap-Band 2.0 FLEX. From a continuum of care perspective, individuals with obesity on GLP-1 therapy are likely potential candidates for Lap-Band bariatric surgery as the next viable anatomies, preserving weight loss treatment. In other words, once GLP-1 patients get a taste of weight loss, you have issues with the drug's accessibility, durability or tolerance. They will contemplate bariatric surgery, especially in the non-invasive procedure like the Lap-Band. Furthermore, as the safest and only adjustable and reversible bariatric surgery, the Lap-Band is ideal for sample specific types of patients like women and childbearing years, who are not able to utilize GLP-1 drugs. Now let me take a few minutes to update you on our progress related to our primary growth pillars. As I mentioned earlier in the call, I want to provide more specifics on the progress made toward our first pillar to deliver shareholder value and ultimately profitability. Specifically, as we consider the impact of GLP-1 receptor agonist prescriptions for weight loss treatment, which has put pressure on the bariatric industry. It was imperative to conduct a thorough evaluation of our operations and swiftly implement substantial cost cutting measures. At the same time, we were channeling investments into the most promising product strategy to drive growth and maintain adherence to critical P&L metrics within our organization. Now Tom will detail the expense savings we have identified, realized and are planning for. In summary, we have identified and implemented additional cost reductions expected to result in lower operating expenses of approximately $8 million in 2024, and more than 50% reduction over 2023, excluding one-time costs. We are optimizing our marketing spending while making additional reductions in consulting services totaling approximately $2.4 million. We have also executed a reduction in force equating to approximately $1.2 million. We have decided to temporarily pause or reset care program and achieve estimated savings of $0.8 million, while we work to augment the ReShape care platform and secure a self-insured employer to provide ReShape care to their employees. We have also planned $4.9 million of reductions for incentive compensation and other payroll-related amounts, all a part of streamlining our team significantly, but without affecting revenue. Taken together, these reductions will allow us to focus and invest in our growth drivers while at the same time extend our cash runway. These changes are bold, necessary and indicative of our commitment to our first pillar, which I established in late 2022. In point of fact, with these 2024 reductions, the company's core operating expenses reduced between 2022 and 2024, an estimated $24 million or 75%. In addition to the necessary cost reduction initiatives related to our first growth pillar, we are continuing to make progress with our cost effective digital lead generation and patient engagement campaign through our partnership with Hive Medical. This platform allows us to set excess advanced lead optimization software that enhances patient engagement and increases patient volume. The software utilizes AISMS platform technology, along with our direct to consumer marketing campaign to help individuals easily book appointments with medical professionals. This has led to an increase in the quality of patient needs and cost reduction in targeted markets. Let's now discuss our progress executing our second growth pillar to expand our portfolio in distribution. In February, the first surgeries using reshapes enhanced Lap-Band 2.0 FLEX were successfully performed. Since then, additional surgeries have taken place and the initial limited launch has gained momentum. This launch represents a significant advancement in improving the overall experience for Lap-Band patients. While we're now only approved to market in the US, we are working to obtain regulatory approvals in both Canada and the EU. The new Flex (NASDAQ:FLEX) technology serves as a relief valve, alleviating discomfort caused by swallowing large pieces of food and designed to eliminate the need for in-office band emergent adjustments as the band temporarily relaxes before returning to its original diameter. Now earlier this year, we had the opportunity to train surgical fellows on the Lap-Band and we also introduced them to the Lap-Band 2.0 FLEX. This was an exciting event because the future of Lap-Band relies on its continued adoption by surgeons and surgical fellows, who are the next generation of bariatric surgeons. based on feedback from current surgeons, including those who have already used the Lap-Band 2.0 FLEX, we believe that the new Flex technology will enable us to engage more surgeons and attract new and existing Lap-Band patients. In June, in San Diego, at this year's annual American Society for metabolic and Bariatric Surgery meeting or the ASMS meeting, we are excited to showcase the FLEX technology to the largest gathering of surgeons and integrated health professionals. All combined to feel there is a momentum building -- there is momentum building and increasing demand for Lap-Band 2.0 FLEX surgery, making it a true catalyst for growth in Lap-Band franchise and the company as a whole. Now it's also important to note that in March, we significantly strengthen ReShapes intellectual property portfolio surrounding the intragastric balloon system, having received a notice of allowance from the US Patent Office and Trademark Office and last week had the patent issue. We will continue to build a defensive moats around our product portfolio, innovation and commercialization efforts and take offensive action to defend our position utilizing non-dilutive funding. Before I turn the call over to Tom, I want to reiterate that we remain confident that with our Lap-Band 2.0 FLEX and legacy Lap-Band, we are uniquely positioned with the safest and most durable organ sparing and reversible weight loss option for those patients that have historically had an aversion to medically managed weight loss and surgery, given the growing body of evidence points to the fact that weight loss to the GLP-1 receptor agonist usage has limitations related co-morbidities and accessibility. We believe that the market opportunity for the Lap-Band 2.0 FLEX and Lap-Band will increase over time. From a continuum of care perspective, these patients are likely potential candidates for bariatric surgery as the next viable weight-loss treatment. I'd like to now turn the call over to Tom Stankovich to provide a recap of our financial performance. Tom?
托马斯·斯坦科维奇:谢谢，保罗。再次感谢大家参加今天下午的网络直播。正如Paul之前提到的，为了应对GLP-1的短期影响和采用，我们在3月份提供了最新消息，我们已经重组了公司，并确定仅在2024年就可以减少约800万美元的成本，即55%。具体而言，从2023年11月和12月开始，将削减约120万美元的资金，并在所有费用类别中削减90万美元的激励薪酬和其他与工资相关的金额。其他核心运营成本已经减少，其中包括在不影响我们持续的营销支出优化的情况下，销售和营销成本减少了240万美元，与我们的重塑护理计划暂停相关的成本总计为80万美元。与一般和行政有关的费用共计130万美元，主要是专业、咨询费和保险费。研发费用约为90万美元，主要包括减少的专利费和咨询费用。到目前为止，我们在减少核心运营费用方面取得了重大进展，在2022年至2024年期间削减了约2400万美元(75%)。事实上，与2023年第一季度相比，今年第一季度我们的总运营费用大幅减少了51%。我们的实际财务的全面讨论可在今天的新闻稿和10-Q。因此，我将花一点时间回顾截至2024年3月31日的第一季度的关键财务指标。截至2024年3月31日的三个月，我们的总收入为190万美元，与2023年同期相比减少了15%，即30万美元。主要原因是销售量下降，主要是由于GLP-1药物。我们将继续专注于新的营销策略，在美国各地的减肥手术中心附近开展有针对性的人工智能支持的数字媒体活动，同时降低成本，提高效率。我们预计，这些努力将在整个2024年继续取得成果。此外，我们预计Lap-Band 2.0 FLEX将于2024年在美国全面推出，这将有助于2024年至2025年的销售增长。截至2024年3月31日和2023年3月31日的三个月的毛利润均为120万美元。截至2024年3月31日的三个月，毛利润占总收入的比例为60%，而2023年同期为54%。毛利百分比的增加是由于公司在2023年底裁员，导致管理费用(主要是工资)减少。截至2024年3月31日的三个月，销售和营销费用从2023年同期的220万美元下降到100万美元，减少了120万美元，降幅为53%。广告和营销费用减少了70万美元，因为我们评估了我们的营销方法，并转向了有针对性的人工智能支持的直接数字营销活动。与薪金有关的支出也减少了50万美元，包括由于销售人员变动和销售额下降而减少的佣金、股票补偿费用和旅费50万美元。截至2024年3月31日的三个月，一般和行政费用减少了230万美元，约为190万美元，减少了56%，而2023年同期为420万美元。减少的主要原因是审计和法律费用等专业服务减少了130万美元，主要是由于2022财年在2023年第一季度进行了重述。公开发行股票的费用和与薪金有关的费用的减少，包括由于人员内部变动而减少约50万美元的股票报酬。该公司还减少了10万美元的租金和保险，并于2023年第二季度将其总部转移到一个较小的设施，以降低成本。截至2024年3月31日的三个月，研发费用为50万美元，与2023年同期保持一致，主要是股票薪酬略有下降。截至2024年3月31日的三个月，非gaap调整后的EBITDA亏损为210万美元，而去年同期亏损为530万美元，减少了320万美元，这主要是由于我们继续努力降低总体运营成本。本季度结束时，我们的净营运资本约为440万美元，主要是由于250万美元的现金和现金等价物以及160万美元的应收账款，我们的资产负债表上保持无债务状态。在2024年的剩余时间里，我们预计我们的收入会增加，运营费用会继续减少。说到这里，我现在把电话交给保罗。
保罗·希基:谢谢，汤姆。在我们开始问答之前，有必要重申一下，正如汤姆和我都详细说明的那样，我们已经并将继续大幅削减所有类别的运营费用，以便我们能够投资于我们的增长计划，包括全面推出Lap-Band 2.0 FLEX。我们为重组公司所采取的迅速而大胆的步骤将有助于确保公司的可持续性和可扩展性。我们继续优先考虑投资，包括营销自动化，以支持可扩展的潜在客户获取，细分市场和以消费者为中心的信息传递，并成为一个更新的网站，以提高患者参与度，并与合格的供应商建立一个无摩擦的预约安排系统，同时进一步降低潜在客户的产生成本。综上所述，我们期望增加Lap-Band程序并最终增加收入。我们将继续与一些行动小组合作，积极寻找和评估我们的并购机会，以扩大我们的投资组合，与变革性技术的竞争有所区别。我们提供一系列安全的、不改变解剖结构的生活方式增强产品，这些产品是药物治疗或更具侵入性治疗的有吸引力的替代品。最后，我们将继续与世界一流的科学顾问委员会合作，继续执行我们的计划，在全球市场上取得成功，这个市场正以历史性的方式向标准化的安全有效的肥胖治疗转变。我们准备好的发言到此结束。现在我们开始回答大家的问题。运营商吗?
接线员:[接线员说明]。既然没有问题，我想把会议交给保罗·希基来做结束语。请继续。
：
：
保罗·希基:谢谢。我们正在盈利的道路上，重组了组织，专注于增加股东价值，建立可持续和可扩展的业务，我们将继续优先寻找协同并购机会，同时继续采用Lap-Band 2.0 FLEX项目，作为公司的增长催化剂。与往常一样，我要感谢我们的员工、董事会成员、客户、顾问顾问、供应商、现有和新股东，感谢你们对我们的持续支持，帮助我们实现成为一流的医生领导的减肥公司的使命。我期待着继续与我们的利益相关者、医疗保健合作伙伴和股东接触。谢谢大家。
接线员:会议到此结束。感谢您参加今天的电话会议。您现在可以断开连接。
本文是在人工智能的支持下生成的，并由编辑审阅。欲了解更多信息，请参阅我们的T&C。
